Circulating tumor cells for EGFR-TKI resistance in NSCLC patients; prospective, multicenter study
Phase 2
- Conditions
- on small cell lung carcinoma with EGFR mutation
- Registration Number
- JPRN-UMIN000015830
- Lead Sponsor
- Teikyo university school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. HIV, HBV, HCV 2. History of Gefitinib, Erlotinib and crizotinib 3. Symptomatic brain metastasis 4. Presence of pulmonary fibrosis or interstitial pneumonia in chest CT 5. Active double cancer 6. Primary physician considered not to be suitable for the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The frequency of detecting T790M in CTC
- Secondary Outcome Measures
Name Time Method